Document 0955
 DOCN  M9620955
 TI    Clinical manifestations and implications of coinfection with
       Mycobacterium kansasii and human immunodeficiency virus type 1.
 DT    9602
 AU    Witzig RS; Fazal BA; Mera RM; Mushatt DM; Dejace PM; Greer DL; Hyslop NE
       Jr; Department of Medicine, Tulane University School of Medicine, New;
       Orleans, Louisiana 70112, USA.
 SO    Clin Infect Dis. 1995 Jul;21(1):77-85. Unique Identifier : AIDSLINE
       MED/96065616
 AB    We conducted a retrospective study to further elucidate the clinical
       presentations and prognosis of disease due to Mycobacterium kansasii in
       patients infected with human immunodeficiency virus (HIV). Forty-nine
       HIV-infected patients first had M. kansasii isolated at a mean CD4 cell
       count of 62/mm3 and at a mean interval of 17 months after the diagnosis
       of AIDS. Seventeen of the 49 patients had disseminated disease caused by
       M. kansasii. Twenty-nine patients had a positive acid-fast smear of
       sputum, and 35 were known to be cigarette smokers. At the time of
       initial isolation of M. kansasii, 13 patients had other concurrent
       pulmonary isolates and 15 had another mycobacterial species concurrently
       isolated (the Mycobacterium avium complex in 13 instances). Patients who
       received antimycobacterial treatment survived longer than those who did
       not. Only one of the 49 patients was definitively determined to be
       colonized with M. kansasii without disease; therefore, it appears that
       pulmonary isolates of M. kansasii in HIV-infected patients are almost
       always associated with disease. The increase in rates of M. kansasii
       disease among HIV-infected patients has paralleled the rise of AIDS in
       Louisiana. So far, this state has recorded more coinfections with M.
       kansasii and HIV than any other.
 DE    Adolescence  Adult  Aged  Aged, 80 and over  Antibiotics/THERAPEUTIC USE
       AIDS-Related Opportunistic Infections/*COMPLICATIONS/DIAGNOSIS/  DRUG
       THERAPY  CD4 Lymphocyte Count  Female  Human  HIV
       Infections/*COMPLICATIONS/DIAGNOSIS/DRUG THERAPY  *HIV-1
       Lung/MICROBIOLOGY  Lung Diseases/MICROBIOLOGY  Male  Middle Age
       Mycobacterium Infections, Atypical/*COMPLICATIONS/DIAGNOSIS/DRUG
       THERAPY  Mycobacterium, Atypical/*ISOLATION & PURIF  Prognosis
       Retrospective Studies  Sputum/MICROBIOLOGY  JOURNAL ARTICLE  REVIEW
       REVIEW OF REPORTED CASES

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).